By priming pancreatic ductal adenocarcinomas with a therapeutic vaccine and a low-dose chemotherapy combination prior to surgery, researchers converted PDACs into cancers that may respond to immunotherapy.
A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national phase III clinical trial
New overall survival data of two phase III clinical trials, LUX-Lung 3 and LUX-Lung 6, demonstrated that patients with advanced non-small cell lung cancer whose tumors have the most common epidermal growth factor receptor mutation lived longer if treated with first-line afatinib compared to chemotherapy.
FDA granted orphan drug designation to ADXS-HPV for the treatment of stage II-IV invasive cervical cancer.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A phase III trial of rolapitant, an investigational neurokinin-1 receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting, was successful in achieving statistical significance for its primary and all secondary endpoints.
In a phase I study, tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Merck announced new biomarker findings from a retrospective analysis of the completed phase III study that compared Erbitux (cetuximab) plus FOLFIRI with FOLFIRI alone.
A study found that it may be safe to postpone androgen deprivation therapy in men with a PSA-only based relapse after prostate surgery or radiation therapy.
The American Society of Clinical Oncology published two clinical practice guidelines on treating women with advanced, HER2-positive breast cancer.
